On September 10, 2026, the Board of Directors appointed Jereme Sylvain as Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with this promotion, Mr. Sylvain entered into an offer letter providing for an annual base salary of $767,000 and an annual target bonus opportunity equal to 75% of his base salary. He retains eligibility for equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan and participates in executive benefit plans. Dexcom operates in the medical device industry, specializing in glucose biosensing technology for diabetes management.
